Child ; China ; epidemiology ; Diagnosis, Differential ; Electroencephalography ; Epilepsy, Reflex ; diagnosis ; epidemiology ; genetics ; physiopathology ; therapy ; Genetic Predisposition to Disease ; Humans ; Light ; adverse effects ; Risk Factors

Objective To detect the possibility of brain damage in the epileptic children with single episodes.Methods The serum and cerebrospinal fluid(CSF)levels of neuron-specific enolase(NSE)in 20 cases with single episodes within 24 hours after seizures and 38 cases of controls were determined respectively by electrochemiluminescence,and the levels of S-100? protein(S-100?) and myelin basic protein(MBP)were determined by enzyme-linked immunosorbent assay.Results The levels of NSE in serum and CSF in epileptic group were(15.01?5.14) ?g/L and(7.84?2.62) ?g/L,respectively,and controls were(10.33?2.48) ?g/L,(3.95?1.58) ?g/L.The levels of S-100? in serum and CSF in epileptic group were(0.39?0.15) ?g/L and(0.59?0.20) ?g/L,respectively,and controls were(0.11?0.05) ?g/L,(0.29?0.19) ?g/L.The levels of MBP in serum and CSF in epileptic group were(0.23?0.09) ?g/L and(0.33?0.07) ?g/L,respectively,and controls were(0.23?0.06) ?g/L,(0.31?0.07) ?g/L.The serum and CSF levels of NSE,S-100? in epileptic group within 24 hours after seizures were significantly higher than those in control group(all P0.05).Conclusions The levels of NSE and S-100? in serum and CSF can reach higher levels within 24 hours after seizures,neuronal damage may result from single episodes.

Hyperglycaemia attenuates?-cell insulin secretion in response to plasma glucose elevation and reduces insulin-mediated glucose transport. The long-standing severe hyperglycaemia may irreversibly damage?-cells. However, in this regard, there are increasing evidences showing that short-term intensive insulin therapy may significantly improve the response to endogenous insulin by normalizing blood glucose, so as to induce a "honeymoon period" for several years in a considerable number of subjects with newly diagnosed type 2 diabetes. Thus, a question has been raised: whether or not insulin therapy should be taken as a part of the strategy of the primary treatment for type 2 diabetes? A number of experts believe that it is an important therapeutic strategy, however, others hold that insulin therapy may yield more cost than benefit and suggest that to halt this cycle of progressive metabolic deterioration by any means may transiently restore metabolic re-compensation in type 2 diabetes. This issue was discussed in the fourth meeting of China Group on Insulin Secretion and in 66th ADA scientific session this year. Here we offer our consideration on this question for your reference.

Humans ; Hypertension, Portal ; physiopathology ; surgery ; Liver ; physiopathology ; Liver Cirrhosis ; complications ; Liver Transplantation ; Portasystemic Shunt, Transjugular Intrahepatic

Humans ; Hypertension, Portal ; etiology ; surgery ; Liver Cirrhosis ; complications ; surgery ; Liver Transplantation ; Portasystemic Shunt, Surgical ; methods

Objective To evaluate the long-term results of rapamycin eluting stent in patients with coronary heart disease.Methods From Dec. 2001 to Nov. 2002, 143 patients were treated with 173 rapamycin eluting stents. Sixteen stents were implanted directly, the others were implanted with pre-dilation. Post-dilations were performed in 52 stents. All patients were administered aspirin and clopidogrel regularly before and after the procedures. Results Procedural succees rate reached 99.3% with completion of the follow-up in 138 patientes averaging (12.8 ?4.3) months. Thirteen patients has suffered with recurrent angina and 1 had acute myocardial infarction. Thirty eight patients received repetition of coronary angiography within 6 to 12 months after the procedure. Five patients showed instent restenosis, of which 4 received target lesion revascularization. The restenosis rate was 13.2% by angiography.Conclusion Rapamycin eluting stent can be used safely and effectively in patient with coronary heart disease, having long-term effect to reduce the restenosis rate after PCI.

Objective To observe the effect of traditional Chinese treating pressure ulcer compound on microcirculation of rats in-vivo.Methods Rats were divided into four groups according to the random number table,includeing high-dose group,low-dose group,positive control group and negative control group.Model rats of microcirculation disturbance were created by dropping epinephrine on partial of mesentery,and then the following indexes of four groups were detected: arteriole diameter,arteriole flow rate,junction of capillary network counts,etc.Results The rats mesentery arteriole diameter variation of positive control group in different time were(74.73±4.23)min,(73.46±4.02)min,(81.60±3.23)min,(93.37±3.84)min,(98.38±3.25) min respectively,and the variation of high-dose group in different time were (72.26± 2.90)min,(72.16 ± 3.20) min,(82.45±2.85)min,(94.64 ± 3.37)min respectively.There was no significant difference between the two groups (P＞0.05).The rats mesentery arteriole flow rate variation of negative control group in different time were (5.06±1.12)min,(3.47±0.97)min,(8.51±1.15)min,(43.55±3.24)min,(56.47±3.54)min respectively,the variation of positive control group were (19.37± 1.81)min,(21.54±2.69) min,(39.86±3.53)min,(86.41 ±4.27) min,(94.35 ± 4.23) min respectively,the variation of high-dose group were (13.73 ± 2.02) min,(22.67 ± 2.48) min,(46.32 ± 4.27) min,(89.18 ± 5.13) min,(95.07 ± 4.67) min respectively,and the variation of low-dose group were (6.22±1.48)min,(10.34±2.09)min,(25.41±2.49)min,(56.87±3.75)min,(74.30±3.18)min respectively.The rats mesentery arteriole flow rate has recovered to the level of before dropping epinephrine by 9 rmin in positive control group and high-dose group,and there were no significant difference between the two groups (P＞0.05),but there were statistical significance when high-dose group and positive control group were compared with low-dose group and negative control group (P＜0.05).The junction of capillary network counts variation in different time were: negative control group 0,16.92± 1.17,39.19±2.65,positive control group 20.66±1.89,36.78±3.04,76.04±4.29,high-dose group 14.33±1.46,43.75±3.74,81.23±3.34,low-dose group 9.50± 1.13,23.19 ± 2.44,55.62 ± 3.46,respectively,the junction of capillary network counts of high-dose group and low-dose group were more than negative control group (P＜ 0.05),and the high-dose group was more than the positive control group (P＜0.05).The resuming time of local microcirculation flow of positive control group (8.23 ±2.61)rmin was relatively equivalent to high-dose group (8.56 ±1.87) min,(P＞0.05).Conclusion Traditional Chinese compound can obviously modify microcirculation disturbance of rats mesentery caused by epinephrine.Its effect showed a dose-effect proportional relationship.

OBJECTIVE:To establish a method for the content determination of muscone in Aiweixin oral liquid. METHODS:After extracting sample by butanol,GC-MS was performed on the column of BD-17 MS with the volume temperature of 270 ℃;the carrier gas was helium with the sample size of 1 μl at the flow rate of 10 ml/min;the split ratio was 20∶1. EI was ion source with the electron energy of 70 eV,ion source temperature of 230 ℃ and quadrupole temperature of 150 ℃;the tuning mode was automatic tuning by quality full scanning with the threshold value of 30 in the range of 30-600 aum. RESULTS:The linear range of muscone was 12.216-61.08 ng(r=0.999 6);RSD of precision test was lower than 2% and the RSDs of reproducibility and stability tests were lower than 3%;the average recovery was 100.24%(RSD=1.58%,n=6). CONCLUSIONS:The method is sensitive, rapid and simple,and can be used for the content determination of muscone in Aiweixin oral lipid.

In the last twenty years, using all-trans retinoic acid (ATRA) as a differentiation inducer, Shanghai Institute of Hematology has achieved an important breakthrough in the treatment of acute promyelocytic leukemia (APL), which realized the theory of reversing phenotype of cells and provided a successful model of differentiation therapy in cancers. Our group first discovered in the world the variant chromosome translocation t(11;17)(q23;q21) of APL, and cloned the PML-RAR alpha, PLZF-RAR alpha and NPM-RAR alpha fusion genes corresponding to the characterized chromosome translocations t(15;17); t(11;17) and t(5;17) in APL. Moreover, establishment of transgenic mice model of APL proved their effects on leukemogenesis. The ability of ATRA to modify the recruitment of nuclear receptor co-repressor with PML-RAR alpha but not PLZF-RAR alpha caused by the variant chromosome translocation elucidated the therapeutic mechanism of ATRA from the molecular level and provides new insight into transcription-modulating therapy. Since 1994, our group has successfully applied arsenic trioxide (As(2)O(3)) in treating relapsed APL patients, with the complete remission rate of 70% - 80%. The molecular mechanism study revealed that As(2)O(3) exerts a dose-dependent dual effect on APL. Low-dose As(2)O(3) induced partial differentiation of APL cells, while the higher dose induced apoptosis. As(2)O(3) binds ubiquitin like SUMO-1 through the lysine 160 of PML, resulting in the degradation of PML-RAR alpha. Taken together, ATRA and As(2)O(3) target the transcription factor PML-RAR alpha, the former by retinoic acid receptor and the latter by PML sumolization, both induce PML-RAR alpha degradation and APL cells differentiation and apoptosis. Because of the different acting pathways, ATRA and As(2)O(3) have no cross-resistance and can be used as combination therapy. Clinical trial in newly diagnosed APL patients showed that ATRA/As(2)O(3) in combination yields a longer disease-free survival time. With the median survival of 18 months, none of the 20 cases in combination treatment relapsed, whereas 7 relapsed in 37 cases in mono-treatment. This is the best clinical effect achieved in treating adult acute leukemia to this day, possibly making APL the first adult curable leukemia. Based on the great success of the pathogenetic gene target therapy in APL, this strategy may extend to other leukemias. Combination of Gleevec and arsenic agents in treating chronic myeloid leukemia has already make a figure both in clinical and laboratory research, aiming at counteracting the abnormal tyrosine kinase activity of ABL and the degradating BCR-ABL fusion protein. In acute myeloid leukemia M(2b), using new target therapy degradating AML1-ETO fusion protein and reducing the abnormal tyrosine kinase activity of c-kit will also lead to new therapeutic management in acute leukemias.
Antineoplastic Agents ; therapeutic use ; Benzamides ; Fusion Proteins, bcr-abl ; genetics ; metabolism ; Humans ; Imatinib Mesylate ; Leukemia, Promyelocytic, Acute ; drug therapy ; genetics ; metabolism ; Oncogene Proteins, Fusion ; genetics ; metabolism ; Piperazines ; therapeutic use ; Protein-Tyrosine Kinases ; antagonists & inhibitors ; metabolism ; Pyrimidines ; therapeutic use ; Receptors, Retinoic Acid ; genetics ; metabolism ; Tretinoin ; therapeutic use